Clinical Trial Update: Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating chemotherapy for metastatic, poorly differentiated Grade 3 neuroendocrine carcinoma of gastroenteropancreatic origin or unkn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor
• Neuroendocrine Carcinoma

Snippet

Sponsor: Centre Hospitalier Universitaire Dijon | Conditions: Neuroendocrine Carcinoma | Phase 2 | Status: RECRUITING